ReviewCold Spring Harbor perspectives in biology2015
Cell of origin for malignant gliomas and its implication in therapeutic development.
Review in Cold Spring Harbor perspectives in biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Leptomeningeal disease in glioblastoma: endgame or opportunity?Journal of neuro-oncology · 2021Pooled it
- Influence of glioblastoma contact with the lateral ventricle on survival: a meta-analysis.Journal of neuro-oncology · 2017Pooled it
- Pathway dysregulation and therapeutic resistance in glioblastoma: molecular mechanisms and emerging therapeutic targets.Future science OA · 2026Review
- ATRX Condensates as Candidate Organizers of Enhancer-Centered Nuclear Microenvironments in Neural Progenitors: A Hypothesis for Enhancer-Associated ATRX Function in Neural Progenitors.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026Review
- α-Synuclein triggers intercellular nanotubes formation to prevent apoptosis in astroglia by promoting stemness.Cell & bioscience · 2026Article
- The molecular asynchrony of single cells.bioRxiv : the preprint server for biology · 2026Article
- Review
- Critical role of cell competition in gliomagenesis.bioRxiv : the preprint server for biology · 2026Article
- Impact of meningioma and glioma on whole-brain dynamics.Scientific reports · 2026Article
- 18ï ¢-Glycyrrhetinic acid suppresses glioblastoma by regulating p38 signaling pathway: an integrative approach combining network analysis, transcriptomics, and experimental assessment.Frontiers in pharmacology · 2026Article
- Learning the cellular origins across cancers using single-cell chromatin landscapes.Nature communications · 2025Article
- Circadian rhythms in pediatric high-grade gliomas may contribute to treatment efficacy.Scientific reports · 2025Article
- Breaking Barriers in Glioblastoma Targeting through Advanced Nanoparticle Cell Membrane Coating.ACS applied materials & interfaces · 2025Article
- Harnessing human iPSC-microglia for CNS-wide delivery of disease-modifying proteins.Cell stem cell · 2025Article
- Tumor-associated long non-coding RNAs show variable expression across diffuse gliomas and effect on cell growth upon silencing in glioblastoma.Scientific reports · 2025Article
- Kinin BPharmaceuticals (Basel, Switzerland) · 2025Article
- Breaking Down Glioma-Microenvironment Crosstalk.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2025Review
- Understanding Neovascularization in Glioblastoma: Insights from the Current Literature.International journal of molecular sciences · 2025Review
- Therapy enhancing chromosome instability may be advantageous forNAR cancer · 2025Article
- Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.Molecular cancer · 2025Review
57 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Malignant glioma remains incurable despite tremendous advancement in basic research and clinical practice. The identification of the cell(s) of origin should provide deep insights into leverage points for one to halt disease progression. Here we summarize recent studies that support the notion that neural stem cell (NSC), astrocyte, and oligodendrocyte precursor cell (OPC) can all serve as the cell of origin. We also lay out important considerations on technical rigor for further exploring this subject. Finally, we share perspectives on how one could apply the knowledge of cell of origin to develop effective treatment methods. Although it will be a difficult battle, victory should be within reach as along as we continue to assimilate new information and facilitate the collaboration among basic scientists, translational researchers, and clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.